The EBMT will be actively participating in the 67th ASH Annual Meeting & Exposition, taking place December 6–9, 2025, in Orlando, Florida, USA.
EBMT representatives will present 38 communications across various oral and poster sessions. Below, you will find the list of presentations, including the title, speaker, location, date, and time. You can click on each title to view the full abstract and presentation details on the ASH website.
Congratulations to all co-authors, and thank you for your continued support!
Oral Abstract Session
Deep immune signature of immune-mediated aplastic anemia patients shows distinct subsets of regulatory T cells associated with response to treatment: Results from the phase 3, randomized EBMT race clinical trial
Speaker: Sila Gerlevik
Room: Hyatt - Plaza Int'l HIJK
Date: Saturday, December 6, 09:45 AM - 10:00 AM EST
Part of session 508. Bone Marrow Failure Acquired: Immune dysregulation and molecular insights
Survey on fertility management and outcomes after cellular therapies, on behalf of the EBMT cellular therapy and immunobiology working party
Speaker: Giorgio Orofino
Room: OCCC - W230
Date: Saturday, December 6, 10:15 AM - 10:30 AM EST
Part of session 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Clinical decision making and supportive care
Impact of conditioning regimen on outcomes of adolescents and young adults AML patients undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. a study from the acute leukemia working party of the european society for blood and marrow transplantation.
Speaker: Enrico Maffini
Room: OCCC - Chapin Theater (W320)
Date: Saturday, December 6, 10:15 AM - 10:30 AM EST
Part of session 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Improving Outcomes by Decreasing Transplant-Related Complications
T cell replete haploidentical transplantation compared to mismatched unrelated allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT
Speaker: Arnon Nagler
Room: OCCC - Chapin Theater (W320)
Date: Saturday, December 6, 10:45 AM - 11:00 AM EST
Part of session 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Improving Outcomes by Decreasing Transplant-Related Complications
Hematopoietic stem cell transplantation in 746 children with osteopetrosis: A study of the inborn errors working party of the EBMT
Speaker: Robert Chiesa
Room: OCCC - W331
Date: Saturday, December 6, 12:30 PM - 12:45 PM EST
Part of session 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Pediatric, Adolescent and Young Adult Patients
The need for a subsequent HCT is a late & continuous risk and with significant impact in overall survival in haemoaglobinopathies: Real-world data from 2000–2022. an analysis of the european society for blood and marrow transplantation (EBMT) hemoglobinopathy working party.
Speaker: Josu de la Fuente
Room: OCCC - W308
Date: Saturday, December 6, 12:45 PM - 01:00 PM EST
Part of session 904. Outcomes Research: Hemoglobinopathies: Clinical Phenotypes and Outcomes in Hemoglobinopathies
Trends in transplantation for patients with myelodysplastic syndrome across recent decades: A registry-based study on behalf of the chronic malignancies working of the EBMT
Speaker: Marie Robin
Room: OCCC - Sunburst Room (W340)
Date: Saturday, December 6, 04:30 PM - 04:45 PM EST
Part of session 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Optimizing Outcomes in Adult and Elderly Patients
Comparison of outcomes in pediatric patients with acute leukemia undergoing allogeneic HLA-haploidentical hematopoietic stem cell transplantation (HSCT) after in vitro a/b T- and CD19-cell depletion or In Vivo administration of post-transplant cyclophosphamide: An EBMT pediatric working party study
Speaker: Daria Pagliara
Room: OCCC - Chapin Theater (W320)
Date: Sunday, December 7, 10:30 AM - 10:45 AM EST
Part of session 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Biologic Predictors and Novel Platforms Integrating CAR T with Transplant
Autologous and allogeneic stem cell transplantation for ALK-positive anaplastic large cell lymphoma: An analysis of the EBMT lymphoma working party
Speaker: Evgenii Shumilov
Room: OCCC - Tangerine Ballroom F2
Date: Monday, December 8, 03:15 PM - 03:30 PM EST
Part of session 625. T Cell, NK Cell, or NK/T Cell Lymphomas: Clinical and Epidemiological: From bench to bedside and retrospective studies to inform treatment consideration in TCL
Better outcomes with haploidentical than matched sibling donors for adult AML patients allo-transplanted in CR with detectable MRD: A study from the global committee and the ALWP of the EBMT.
Speaker: Yishan Ye
Room: OCCC - Valencia Room W415A
Date: Monday, December 8, 05:00 PM - 05:15 PM EST
Part of session 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Precision AML Care; Reducing Relapse and Enhancing Survival
Poster Abstract Session
Outcomes of allogeneic hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP
Speaker: Maria Carmen Martinez Munoz
Room: OCCC - West Halls B3-B4
Date: Saturday, December 6, 05:30 PM - 07:30 PM EST
Part of session 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster I
Allogeneic hematopoietic cell transplantation in TP53-mutated Acute Myeloid Leukemia patients with active disease: A study from the global committee and the acute leukemia working party of the EBMT
Speaker: Lin Li
Room: OCCC - West Halls B3-B4
Date: Saturday, December 6, 05:30 PM - 07:30 PM EST
Part of session 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Impact of prior B-cell-directed immunotherapy on the outcome of CD19 CAR T-cell therapy in aggressive B-cell lymphoma - an analysis of the EBMT and the GoCART coalition
Speaker: Jan Christian Schroeder
Room: OCCC - West Halls B3-B4
Date: Saturday, December 6, 05:30 PM - 07:30 PM EST
Part of session 628. Aggressive Lymphomas: Cellular Therapies: Poster I
Comparable outcomes of haploidentical, sibling, and unrelated donor transplantation for adult T-ALL in second remission: a study from the global committee and ALWP of the EBMT
Speaker: Jia Chen
Room: OCCC - West Halls B3-B4
Date: Saturday, December 6, 05:30 PM - 07:30 PM EST
Part of session 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
CAR T-cell therapy versus autologous HSCT in patients with large B-cell lymphoma in complete remission: An analysis from the EBMT lymphoma working party
Speaker: Remy Dulery
Room: OCCC - West Halls B3-B4
Date: Saturday, December 6, 05:30 PM - 07:30 PM EST
Part of session 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster I
Allogeneic hematopoietic cell transplantation in TP53-mutated Acute Myeloid Leukemia patients with active disease: A study from the global committee and the acute leukemia working party of the EBMT
Speaker: Lin Li
Room: OCCC - West Halls B3-B4
Date: Saturday, December 6, 05:30 PM - 07:30 PM EST
Part of session 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Matched sibling donors still provide superior survival outcomes in older patients with AML in second complete remission. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation
Speaker: Depei Wu
Room: OCCC - West Halls B3-B4
Date: Saturday, December 6, 05:30 PM - 07:30 PM EST
Part of session 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster I
Real world outcomes of FLT3 inhibitors and hypomethylating agents as post transplant prophylaxis in Acute Myeloid Leukemia patients transplanted in first complete remission: From the EBMT acute leukemia working party
Speaker: Nour Moukalled
Room: OCCC - West Halls B3-B4
Date: Sunday, December 7, 06:00 PM - 08:00 PM EST
Part of session 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II
Allo-HCT outcomes for AML patients with NUP98 rearrangements: A study on behalf of the global committee, the ALWP and the PDWP of the EBMT
Speaker: Yishan Ye
Room: OCCC - West Halls B3-B4
Date: Sunday, December 7, 06:00 PM - 08:00 PM EST
Part of session 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster II
Outcomes of autologous hematopoietic stem cell transplantation in nodular lymphocyte-predominant Hodgkin lymphoma: A registry-based study from the EBMT-LWP
Speaker: Maria Carmen Martinez Munoz
Room: OCCC - West Halls B3-B4
Date: Sunday, December 7, 06:00 PM - 08:00 PM EST
Part of session 624. Hodgkin Lymphomas: Clinical and Epidemiological: Poster II
Outcomes of multiple myeloma (MM) patients with del 17p as a sole high risk cytogenetic abnormality who underwent either single or tandem upfront autologous stem cell transplant approaches in EBMT centres between 2016 and 2022
Speaker: Conal Houstoun
Room: OCCC - West Halls B3-B4
Date: Sunday, December 7, 06:00 PM - 08:00 PM EST
Part of session 907. Outcomes Research: Plasma Cell Disorders: Poster II
Autologous, allogeneic haemopoietic stem cell transplantation and CART cell therapy for transformed Waldenström’s macroglobulinemia to high grade non-Hodgkin lymphoma. real world outcomes report from the lymphoma working party of the european society for blood and marrow transplantation (LWP EBMT)
Speaker: Charalampia Kyriakou
Room: OCCC - West Halls B3-B4
Date: Sunday, December 7, 06:00 PM - 08:00 PM EST
Part of session 628. Aggressive Lymphomas: Cellular Therapies: Poster II
Young (35 years) matched sibling donors for allogeneic transplantation with post-transplantation cyclophosphamide in patients with secondary acute myeloid leukemia in first complete remission: A study from the ALWP/EBMT
Speaker: Arnon Nagler
Room: OCCC - West Halls B3-B4
Date: Sunday, December 7, 06:00 PM - 08:00 PM EST
Part of session 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster II
Thymoglobuline and grafalon show comparable transplant outcomes in patients with aplastic anemia undergoing allogeneic stem cell transplantation: A multicenter EBMT saawp study of 1603 patients
Speaker: Fabian Beier
Room: OCCC - West Halls B3-B4
Date: Sunday, December 7, 06:00 PM - 08:00 PM EST
Part of session 508. Bone Marrow Failure: Acquired: Poster II
Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party
Speaker: Ali Bazarbachi
Room: OCCC - West Halls B3-B4
Date: Sunday, December 7, 06:00 PM - 08:00 PM EST
Part of session 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster II
Allogeneic stem cell transplantation with post-transplantation cyclophosphamide in patients with acute myeloid leukemia achieving first complete remission after one versus two inductions: A study from the ALWP/EBMT
Speaker: Arnon Nagler
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 06:00 PM EST
Part of session 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Prognostic analysis of salvage allogeneic HCT in acute leukemia patients relapsing after autologous HCT: a study from the acute leukemia working party of the EBMT
Speaker: Mingyang Wang
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 08:00 PM EST
Part of session 723. Allogeneic Transplantation: Long-term Follow-up, Complications, and Disease Recurrence: Poster III
Bridging to CD19 CAR T-cell therapy for LBCL: An analysis of 1,154 patients by the EBMT lymphoma working party and the gocart coalition
Speaker: Philipp Berning
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 08:00 PM EST
Part of session 628. Aggressive Lymphomas: Cellular Therapies: Poster III
Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP
Speaker: Iman Abou Dalle
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 08:00 PM EST
Part of session 908. Outcomes Research: Myeloid Malignancies: Poster III
Impact of thiotepa dose in haploidentical allogeneic stem cell transplantation with thiotepa-busulfan-fludarabine conditioning for Acute Myeloid Leukemia in remission: A retrospective analysis of the EBMT acute leukemia working party
Speaker: Fabio Andreozzi
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 08:00 PM EST
Part of session 721. Allogeneic Transplantation: Conditioning Regimens, Engraftment, and Acute Toxicities: Poster III
Next-generation sequencing-based mutation profile in secondary compared to de novo acute myeloid leukemia patients undergoing allogeneic stem cell transplantation: A study from the ALWP/EBMT
Speaker: Arnon Nagler
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 06:00 PM EST
Part of session 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Current practices, organizational structures, technologies and challenges in developing atmps: A survey by dare-NL, nxtgen hightech, T2EVOLVE and ctiwp of EBMT - a gocart-coalition initiative
Speaker: Anil Deshantri
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 08:00 PM EST
Part of session 711. Cell Collection and Manufacturing of HSPCs, CAR-T Cells, and Other Cellular Therapy Products: Poster III
Outcomes of 544 patients with t(6;9) Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation: An EBMT Study on behalf of the acute leukemia working party (ALWP) and the pediatric diseases working party (PDWP)
Speaker: Fabio Andreozzi
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 06:00 PM EST
Part of session 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Venetoclax in combination with hypomethylating agents shows promising activity in Acute Myeloid Leukemia with late relapse post allogeneic stem cell transplant: From the EBMT acute leukemia working party
Speaker: Nour Moukalled
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 06:00 PM EST
Part of session 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Improved survival in Philadelphia Chromosome–Positive acute lymphoblastic leukemia with pre-transplant second- and third-generation TKIs and post-transplant prophylactic maintenance: A study from the EBMT ALWP
Speaker: Iman Abou Dalle
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 08:00 PM EST
Part of session 906. Outcomes Research: Lymphoid Malignancies Excluding Plasma Cell Disorders: Poster III
The impact of additional cytogenetic abnormalities and complex karyotype on outcomes of adult patients with Philadelphia-positive acute lymphoblastic leukemia undergoing allogeneic stem cell transplantation in first complete remission: A study from the ALWP/EBMT
Speaker: Arnon Nagler
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 06:00 PM EST
Part of session 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III
Long-term outcomes of syngeneic transplantation in multiple myeloma: Valuable legacy or obsolete option? a study from the chronic malignancies working party of the EBMT
Speaker: Iman Abou Dalle
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 08:00 PM EST
Part of session 907. Outcomes Research: Plasma Cell Disorders: Poster III
Comparison of autologous HCT versus haploidentical donor HCT for Ph+ B-ALL patients following TKI therapy. a study from the global committee and the acute leukemia working party of the european society for blood and marrow transplantation
Speaker information: Yuhua Ru
Room: OCCC - West Halls B3-B4
Date: Monday, December 8, 06:00 PM - 06:00 PM EST
Part of session 732. Allogeneic Transplantation: Disease Response and Comparative Treatment Studies: Poster III